Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland R Griffiths

Showing results (131-140 of 136) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 136 results.
Neuropharmacology|August 20, 2022
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act schedulingJack E Henningfield, Marion A Coe, Roland R Griffiths, et al.
The International Journal of Neuropsychopharmacology|February 14, 2016
Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in HumansAna Elda Maqueda, Marta Valle, Peter H Addy, et al.
Frontiers in Psychiatry|October 5, 2023
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal surveySandeep M Nayak, Hillary Jackson, Nathan D Sepeda, et al.
JAMA Psychiatry|November 30, 2022
Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A ReviewBrian D Kiluk, Bethea A Kleykamp, Sandra D Comer, et al.
JAMA|August 31, 2023
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical TrialCharles L Raison, Gerard Sanacora, Joshua Woolley, et al.
Frontiers in Medicine|September 6, 2021
Recent Progress in Lyme Disease and Remaining ChallengesJason R Bobe, Brandon L Jutras, Elizabeth J Horn, et al.
Pageof 14

Showing results (131-140 of 136) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 136 results.
Neuropharmacology|August 20, 2022
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act schedulingJack E Henningfield, Marion A Coe, Roland R Griffiths, et al.
The International Journal of Neuropsychopharmacology|February 14, 2016
Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in HumansAna Elda Maqueda, Marta Valle, Peter H Addy, et al.
Frontiers in Psychiatry|October 5, 2023
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal surveySandeep M Nayak, Hillary Jackson, Nathan D Sepeda, et al.
JAMA Psychiatry|November 30, 2022
Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A ReviewBrian D Kiluk, Bethea A Kleykamp, Sandra D Comer, et al.
JAMA|August 31, 2023
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical TrialCharles L Raison, Gerard Sanacora, Joshua Woolley, et al.
Frontiers in Medicine|September 6, 2021
Recent Progress in Lyme Disease and Remaining ChallengesJason R Bobe, Brandon L Jutras, Elizabeth J Horn, et al.
Pageof 14